Apellis Pharmaceuticals Inc (NAS:APLS) Stock News, Headlines & Updates
Apellis Pharmaceuticals Inc Stock News from GuruFocus
- 1
- 2
Jul 24, 2025
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results | APLS Stock News
GuruFocus News • 6:19am
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
Marketwired • 6:00am
Jul 18, 2025
APLS: Baird Maintains Outperform Rating, Raises Price Target | APLS Stock News
GuruFocus News • 7:30am
Apellis (APLS) Price Target Increased by Baird Analyst | APLS Stock News
GuruFocus News • 6:46am
Jul 16, 2025
APLS Stock Update: B of A Securities Raises Price Target | APLS Stock News
GuruFocus News • 6:32am
Apellis (APLS) Price Target Raised by BofA | APLS Stock News
GuruFocus News • 5:17am
Jul 15, 2025
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting | APLS Stock News
GuruFocus News • 6:22am
Apellis Pharmaceuticals Inc (APLS) Announces Key Presentations at ASRS Annual Meeting | APLS stock news
GuruFocus News • 6:01am
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
Marketwired • 6:00am
Jul 02, 2025
Apellis Pharmaceuticals (APLS) Receives Price Target Boost from Morgan Stanley | APLS Stock News
GuruFocus News • 10:31am
Jul 01, 2025
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan) | APLS Stock News
GuruFocus News • 6:18am
Apellis Pharmaceuticals Secures $300 Million in Royalty Agreement with Sobi | APLS stock news
GuruFocus News • 6:07am
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
Marketwired • 6:00am
Jun 06, 2025
Apellis Pharmaceuticals (APLS) Reports Promising Empaveli Data
GuruFocus News • 10:56am
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
Marketwired • 9:00am
Apellis Pharmaceuticals (APLS) Reports Promising Phase 3 Study Results for EMPAVELI | APLS Stock News
GuruFocus News • 8:45am
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN | APLS Stock News
GuruFocus News • 8:31am
Jun 04, 2025
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference | APLS Stock News
GuruFocus News • 6:21am
Apellis Pharmaceuticals Inc (APLS) to Present at Goldman Sachs Annual Global Healthcare Conference | APLS stock news
GuruFocus News • 6:06am
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Marketwired • 6:00am
Jun 02, 2025
Wells Fargo Adjusts Price Target for Apellis (APLS) to $29 | APLS Stock News
GuruFocus News • 11:15am
Apellis Pharmaceuticals (APLS) Receives Price Target Boost from Wells Fargo | APLS Stock News
GuruFocus News • 11:01am
Wells Fargo Adjusts Price Target on Apellis (APLS) Amid Product Launch Anticipation | APLS Stock News
GuruFocus News • 5:46am
May 22, 2025
APLS: Citigroup Lowers Price Target for Apellis Pharmaceuticals | APLS Stock News
GuruFocus News • 12:30pm
Apellis (APLS) Target Price Reduced by Citi Amidst Adjusted Growth Outlook | APLS Stock News
GuruFocus News • 5:15am
May 14, 2025
Mizuho Lowers Price Target for Apellis Pharmaceuticals (APLS) | APLS Stock News
GuruFocus News • 10:31am
Apellis (APLS) Faces Price Target Cut as Challenges Persist | APLS Stock News
GuruFocus News • 7:12am
May 09, 2025
Raymond James Downgrades Apellis Pharmaceuticals (APLS) with Price Target Cut | APLS Stock News
GuruFocus News • 12:02pm
APLS: Apellis Pharmaceuticals Stock Downgraded by B of A Securities | APLS Stock News
GuruFocus News • 8:33am
BofA Adjusts Apellis (APLS) Rating to Neutral, Lowers Price Target | APLS Stock News
GuruFocus News • 5:31am
Apellis (APLS) Faces Downgrade Amid Sales Volatility Concerns | APLS Stock News
GuruFocus News • 4:45am
May 08, 2025
Apellis Pharmaceuticals (APLS) Analyst Rating Update by RBC Capital | APLS Stock News
GuruFocus News • 12:35pm
Apellis (APLS) Price Target Reduced by Scotiabank Analyst | APLS Stock News
GuruFocus News • 9:46am
Apellis Pharmaceuticals (APLS) Price Target Lowered by Scotiabank | APLS Stock News
GuruFocus News • 9:42am
Apellis Pharmaceuticals (APLS): Wells Fargo Lowers Price Target to $26 | APLS Stock News
GuruFocus News • 8:42am
Apellis Pharmaceuticals (APLS) Target Price Lowered by Analyst | APLS Stock News
GuruFocus News • 8:01am
Apellis Pharmaceuticals (APLS) Price Target Reduced by Analyst | APLS Stock News
GuruFocus News • 6:50am
Apellis (APLS) Faces Target Price Cut by Wells Fargo | APLS Stock News
GuruFocus News • 6:16am
Apellis Pharmaceuticals Inc (APLS) Q1 2025 Earnings Call Highlights: Strong Market Leadership Amidst Revenue Challenges
GuruFocus News • 1:13am
Decoding Apellis Pharmaceuticals Inc (APLS): A Strategic SWOT Insight
GuruFocus News • 11:10pm
- 1
- 2
Show
Entries
Headlines
Total 0- 1
No recent news